SRCP1 reduced some aggregated SOD1 protein in ALS models but did not extend mouse survival
Original source
Viral vector gene delivery of the novel chaperone protein SRCP1 to modify insoluble protein in in vitro and in vivo models of ALS. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Mouse, Animal
Related topics
Researchers tested viral delivery of serine-rich chaperone protein 1 (SRCP1) in cell, motor-neuron and mouse models of amyotrophic lateral sclerosis (ALS). SRCP1 reduced insoluble mutant SOD1 in cultured cells and modestly reduced SOD1 in the brains and spinal cords of ALS mice. It did not reduce insoluble protein in patient-derived motor neurons or improve mouse survival.
Why this matters
The findings suggest that SRCP1’s effects depend on the protein and model involved. This was laboratory and animal research, so it does not change treatment for people with ALS.
Limitations and context
This was preclinical research, not a clinical trial. Results differed across models, and SRCP1 did not improve survival in the mice. The study also found no reduction of insoluble protein in motor neurons derived from people with ALS; further research would be needed to determine whether SRCP1 has therapeutic potential in humans.